8.87
-0.10 (-1.11%)
| Previous Close | 8.97 |
| Open | 8.90 |
| Volume | 408,294 |
| Avg. Volume (3M) | 1,341,111 |
| Market Cap | 606,507,520 |
| Price / Sales | 20.17 |
| 52 Weeks Range | |
| Earnings Date | 7 Nov 2024 |
| Operating Margin (TTM) | -432.95% |
| Diluted EPS (TTM) | -5.74 |
| Current Ratio (MRQ) | 5.73 |
| Operating Cash Flow (TTM) | -247.11 M |
| Levered Free Cash Flow (TTM) | -179.77 M |
| Return on Assets (TTM) | -57.67% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Phathom Pharmaceuticals, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.25 |
|
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 7.69% |
| % Held by Institutions | 109.32% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 30 Sep 2024 | 7,464,572 |
| Gilder Gagnon Howe & Co Llc | 30 Sep 2024 | 1,622,883 |
| Checkpoint Capital L.P. | 30 Sep 2024 | 1,504,307 |
| 52 Weeks Range | ||
| Median | 26.00 (193.12%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 13 Sep 2024 | 26.00 (193.12%) | Buy | 18.30 |
| 06 Sep 2024 | 26.00 (193.12%) | Buy | 17.72 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 07 Nov 2024 | Announcement | Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates |
| 04 Nov 2024 | Announcement | Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences |
| 28 Oct 2024 | Announcement | Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024 |
| 27 Oct 2024 | Announcement | Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |